Open access
Impact of Organ‐Specific Severe Immune‐Related Adverse Events on Long‐Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5‐Year Multicenter Multistate Analysis
Y. Tasaki
Kazumasa Sato
S. Hamamoto
Y. Sugiyama
Hiroaki Ikoma
K. Kawase
Hiroko Suzuki
Yusuke Noda
Masayuki Usami
Yohei Tsubouchi
Ryuga Kato
Takuya Sakata
Misato Tomita
Yoshihisa Mimura
Takashi Nagai
R. Unno
T. Etani
T. Naiki
T. Yasui
Yoko Furukawa-Hibi
Medicine
Abstract
Immune‐related adverse events (irAEs) frequently occur during combination immune checkpoint inhibition. However, their prognostic impact may vary according to organ involvement and severity. In this study, we exploratorily evaluated whether severe non‐endocrine irAEs represent a temporally distinct and prognostically unfavorable clinical phenotype in patients with metastatic renal cell carcinoma (mRCC) treated with ipilimumab plus nivolumab.